These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22562298)

  • 21. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
    Fuest M; Kotliar K; Walter P; Plange N
    Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections.
    Lemos V; Cabugueira A; Noronha M; Abegão Pinto L; Reina M; Branco J; Gomes T
    Ophthalmologica; 2015; 233(3-4):162-8. PubMed ID: 25791262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber.
    Güler M; Capkın M; Simşek A; Bilak S; Bilgin B; Hakim Reyhan A; Fırat M
    Curr Eye Res; 2014 Oct; 39(10):989-93. PubMed ID: 24588314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
    Omay E; Elgin U; Sen E; Yilmazbas P
    Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
    Wu L; Evans T
    Arch Soc Esp Oftalmol; 2010 Nov; 85(11):364-9. PubMed ID: 21277463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema.
    Al-Abdullah AA; Nowilaty SR; Asghar N; Al-Kharashi AS; Ghazi NG
    Retina; 2015 Mar; 35(3):440-8. PubMed ID: 25285810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
    Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
    Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Dorzolamide/Timolol or Brinzolamide/Timolol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension.
    Kim GN; Han YS; Chung IY; Seo SW; Park JM; Yoo JM
    Semin Ophthalmol; 2013 Mar; 28(2):61-7. PubMed ID: 23448557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections.
    Shoeibi N; Ghosi Z; Jafari H; Omidtabrizi A
    Int Ophthalmol; 2021 Mar; 41(3):1081-1090. PubMed ID: 33389369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrasound biomicroscopy study of vitreous incarceration subsequent to intravitreal injections.
    Hodjatjalali K; Riazi M; Faghihi H; Khorami A
    Can J Ophthalmol; 2012 Feb; 47(1):24-7. PubMed ID: 22333847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreous bevacizumab injection: an experimental study in New Zealand white rabbits.
    Cortez RT; Ramirez G; Collet L; Thakuria P; Giuliari GP
    Arch Ophthalmol; 2010 Jul; 128(7):884-7. PubMed ID: 20625050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
    Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
    Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
    Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
    Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Necessity of the Honan intraocular pressure reducer in cataract surgery using topical anesthesia.
    Black EH; Cohen KL; Tripoli NK; Winslow PA
    J Cataract Refract Surg; 1999 Feb; 25(2):223-6. PubMed ID: 9951668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
    Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
    Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
    Kiddee W; Montriwet M
    PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.
    Song S; Yu XB; Dai H
    Indian J Ophthalmol; 2016 Oct; 64(10):762-766. PubMed ID: 27905340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of the Honan intraocular pressure reducer in sub-Tenon's anesthesia.
    Vallance JH; Patton N; Ferguson A; Bennett HG
    J Cataract Refract Surg; 2004 Feb; 30(2):433-6. PubMed ID: 15030837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.